Discover our pipeline and understand how our targeted approaches are being developed.

Sitryx Pipeline

The Sitryx Product Engine

Driving discovery through the unique exploitation of cross-discipline expertise in drug development

Sitryx Product Engine

Sitryx’s novel programmes

Sitryx is building a broad and differentiated pipeline of first- and best-in-class disease modifying therapeutics by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.

Key proprietary programs

  • SYX-5219 – for the treatment of atopic dermatitis

    SYX-5219 is a pyruvate kinase M2 activator which modulates B and T lymphocyte activity at the specific site of inflammation to reduce inflammation in the skin

  • SIT-052 – for the treatment of pulmonary fibrosis and COPD

    Sitryx’s SIT-052 is a GLS1 inhibitor taken via an inhaled approach for the induction of the selective breakdown of senescent cells which contribute too ongoing fibrosis and inflammation in pulmonary fibrosis. Potential to be first in class treatment for patients with IPF, the inhaled approach is optimised for direct delivery into the lungs, maximising drug exposure.

  • SIT-033 – for the treatment of ulcerative colitis

    SIT-033 is a SIK2 Inhibitor, which unlike early SIK inhibitors, is able to selectively target isozymes to maximise efficacy and therapeutic index in ulcerative colitis. Sitryx’s isozyme selective SIK2 inhibition offers the potential for sustained disease remission and improved safety profile in moderate to severe ulcerative colitis.

ProgramHit-to-LeadLead OptimisationPre-clinicalPhase 1Partner
SYX-5219PKM2Atopic dermatitis
SIT-052GLS1Pulmonary fibrosis
SIT-033SIK2Inflammatory bowel disease
Discovery pipelineMultiple
SYX-1042Itaconate mimeticAutoimmune indications
SIT-047OCMAutoimmune indications

Patient perspectives

Intervening in cell metabolism, to reverse and resolve inflammation and tissue damage, has the potential to bring about better outcomes for patients and enable a broader population to achieve remission from chronic autoimmune and inflammatory disease.